Skip to main content
CRMD logo

CorMedix Inc. (CRMD) Stock: Price, Forecast & Analyst Target

CorMedix Inc. (CRMD) — MoonshotScore 46/100 (Fair band), calculated Nov 18, 2026. Price $5.27 (+3.74%), as of the Nov 20, 2026 trading session; market cap $419M.

Educational signal · not a buy or sell recommendation · How to read this

$5.27 +$0.19 (+3.74%) Market Cap $419M

CorMedix Inc. · CRMD · NASDAQ

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Their lead product candidate, DefenCath/Neutrolin, aims to reduce catheter-related infections and thrombosis.

Price as of Nov 20, 2026

Key Statistics

46 of 100

MoonshotScore v2 · CorMedix (CRMD)

Fair
Business Quality Elite (92)
Financial Safety Okay (57)
Valuation Cheap (99)
Growth Durability Compounding (94)
Momentum Slipping (32)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and elite growth, at a dirt-cheap price. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone and reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Slipping.

  • quarterly revenue $55M (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 6 of the last 8 reports
  • Altman Z 1.67 · Piotroski F 5

Holding back: weak price trend

Helping: business quality, an attractive price, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CRMD (58 recorded, newest six shown)
RecordedScoreBand
91Exceptional
49Fair
49Fair
46Fair
46Fair
46Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$5.27
Change on the day+3.74%
52-week range$4.65 – $13.02
Market capitalisation$419M—
Price / earnings (trailing)5.84
Shares traded on the day3.61M

Price & events

Other perspectives

Council score for CorMedix (CRMD): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Strong
Growth Durability Strong
Momentum Weak

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Strong
Margin of Safety Undervalued
Profit Margin Moderate
Revenue Growth Strong
Debt/Equity Neutral
ROE Moderate
Gross Margin Strong

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 16, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is CorMedix (CRMD), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CorMedix Inc. (CRMD) is listed on NASDAQ. It employs 191 people and is led by Joseph Todisco. In Q3 FY2026 it reported revenue of $55M and net income of -$15M. The market values it at $419M.

2 · Latest results

What do the latest results show for CorMedix (CRMD)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $55M. Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$55M-$15M-$0.19 (diluted)
Q2 FY2026$102M$26M$0.28 (diluted)
Q1 FY2026$127M$39M$0.42 (diluted)
Q4 FY2025$129M$14M$0.15 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for CorMedix (CRMD)?

Short answer

The MoonshotScore pillars rate business quality, an attractive price, durable growth as strengths. What is holding it back is weak price trend. The distress and quality screens read Altman Z 1.67 · Piotroski F 5. Trailing ratios: ROE 15.3% · ROA 12.7% · current ratio 2.43.

4 · What to check next?

What should you watch next at CorMedix (CRMD)?

Short answer · as of

Current published price targets run low $13.00 · high $19.00 · consensus $15.33 · median $14.00 against a quoted price of $5.27 (as of Nov 20, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does CorMedix compare with its peers?

Short answer

CorMedix's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$11.54 Nov 20, 2026$817M69 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$19.19 Nov 20, 2026$1.18B66 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.43 Nov 20, 2026$1.02B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M63 5-pillar Nov 18, 2026
Tango Therapeutics, Inc. (TNGX) Named competitor$21.73 Nov 20, 2026$3.68B62 5-pillar Nov 18, 2026
CorMedix (CRMD) — this page$5.27$419M46

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$13.00 – $19.00
Consensus target
$15.33
Median target
$14.00

Consensus record · Captured .

Measured against a quoted price of $5.27 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 18, 2026

Transactions
5
Identified insiders
4
Purchases
0
Sales
0
Other transactions
5

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CRMD in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CRMD in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about CorMedix (CRMD)?

Read these with our analysis →

Investor Questions: CRMD Stock

These answers are editorial: 1 of these 9 answers is drawn from the CRMD research dossier (written May 5, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CRMD?

CRMD carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is CRMD a good stock to buy?

Stock Expert AI does not rate CRMD buy, sell or hold. CorMedix Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CRMD stock price today?

The last price recorded for CorMedix Inc. (CRMD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CRMD price target?

The analyst consensus price target for CorMedix Inc. (CRMD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about CRMD stock?

Analyst coverage of CorMedix Inc. (CRMD) reflects a focus on the potential of DefenCath/Neutrolin and its impact on the market for catheter-related infection prevention.

What are the key factors to evaluate for CRMD?

CorMedix Inc. (CRMD) holds a MoonshotScore in the low range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Direct-to-patient marketing could help to drive demand for DefenCath/Neutrolin and increase its market share. Not financial advice.

How frequently does CRMD data refresh on this page?

CRMD's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CRMD's recent stock price performance?

CorMedix Inc. (CRMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary anti-infective solution (DefenCath/Neutrolin). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CRMD overvalued or undervalued right now?

The trailing P/E of CorMedix Inc. (CRMD) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 5, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 21 figures on this page — 13 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.